FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:864-865 March 24, 1994 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Harris, C. C. PubMed Citation

To the Editor: Harris and Hollstein (Oct. 28 issue)¹ reviewed the clinical implications of the p53 tumor-suppressor gene. Of particular interest to clinicians is the prognostic importance of p53 mutations. The authors mentioned that there is now more and more evidence of a correlation between the loss of p53 function and shortened survival. They argued that one might theoretically expect the loss of p53 function to be associated with more rapidly advancing disease. They also referred to some recent studies demonstrating that gene amplification is tremendously enhanced in cells lacking normal p53. However, they did not discuss recent results that . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Rutz, H. P. (1994). Cancer Therapy Meets p53. NEJM 331: 1314-1315 [Full Text]